In a regulatory filing on August 10, pharmaceutical titan Merck & Company, Inc. (NYSE:MRK) disclosed holding 1,214,126 shares of micro-cap AI immunology firm Evaxion A/S (NASDAQ:EVAX). Evaxion shares bumped up 2% to $3.17 in early trading on the news. The position follows Merck’s September 2025 decision to exercise its option to in-license EVX-B3, Evaxion’s discovery-stage vaccine candidate against an undisclosed bacterial pathogen. Further lifting sentiment, Argus raised its price target on Merck on August 11 from $130 to $145 with a Buy rating, citing regulatory approvals, clinical progress, M&A activity, pipeline depth, and a rising dividend.
Financial Comparison: Mega-Cap Commercial Cash Flow vs. Pre-Revenue Biotech
Comparing financials between these two companies highlights two entirely different tiers of the biotech ecosystem. Merck & Company, Inc. (NYSE:MRK) operates as a mega-cap commercial powerhouse, posting Q2 2026 revenue of $16.6 billion (up 5% year-over-year), driven by $8.4 billion from KEYTRUDA and $588 million from WINREVAIR. While Merck posted a GAAP net loss of $1.335 billion ($(0.54) EPS) due to a temporary $5.7 billion ($2.31 per share) R&D charge from acquiring Terns Pharmaceuticals, it raised full-year sales guidance to $66.3B–$67.3B.
Conversely, Evaxion A/S (NASDAQ:EVAX)’s Q1 2026 results reflect a typical early-stage, pre-revenue biotech model. Generating $0 in quarterly revenue, Evaxion reported a net loss of $3.6 million, translating to a loss per share of $(0.50) as it funds clinical trials and AI platform development through capital raises. Financial strength heavily favors Merck, whose massive cash flow allows it to absorb deal charges while directly funding early-stage partners like Evaxion.
Bull and Bear Cases
The Bull Case for Merck relies on its commercial scale, strong dividend growth, and aggressive M&A pipeline expansion to offset the eventual KEYTRUDA patent cliff. For Evaxion, the bull thesis rests on validation; having a $280+ billion pharma leader hold a direct equity stake and license its AI-discovered antigens (EVX-B3) provides rare credibility for a micro-cap platform.
The Bear Case for Merck centers on margin pressure from heavy acquisition-related R&D expenses and ultimate revenue replacement risks. For Evaxion, the primary bear risk is continuous cash burn and equity dilution, alongside the vulnerability of relying heavily on a single major partner to advance its assets.
Insider Monkey’s Hedge Fund Data Analysis
Insider Monkey’s institutional database shows modest institutional rebalancing for Merck, while elite funds are making tiny, targeted bets on Evaxion. Merck’s hedge fund holdings dropped slightly from 100 funds in Q4 2025 to 98 funds in Q1 2026, though top holders remain heavily invested, Ken Fisher’s Fisher Asset Management holds 38.5 million shares ($4.95 billion, +46%), and Harris Associates holds 12.07 million shares ($1.55 billion).
Meanwhile, Evaxion saw fund holdings tick up from 3 funds to 4 funds in Q1 2026. Specialized healthcare and quantitative funds hold small positions, led by Neil Shahrestani’s Ikarian Capital (74,698 shares; $231,564) and Ken Griffin’s Citadel Investment Group (36,584 shares; $113,410, +106%).
Conclusion: What Investors Should Watch Next
Merck & Company, Inc. (NYSE:MRK)’s equity disclosure proves that big pharma’s appetite for AI-driven vaccine platforms is active and tangible. Moving forward, Merck investors should track integration of its recent acquisitions and Phase 3 trial readouts. Evaxion A/S (NASDAQ:EVAX) investors must monitor upcoming preclinical progress on the EVX-B3 program, potential milestone payments from Merck, and updates regarding its operating cash runway.
While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
